Staggering Results Show HIV-Transmission Reduced 100% with Twice-Yearly Lenacapavir Injection

A 2-stage trial testing a new and acclaimed HIV-prevention drug has shown almost unthinkable results of no new infections among a sample size of 3,200 participants.

Called PURPOSE 1, the aim of the first trial was testing a subcutaneous injection of the drug Lenacapavir given twice a year to people in a high-HIV-incidence country, which in this case was Uganda or South Africa.

The results were nothing short of extraordinary—100% efficacy, not a single young woman contracted HIV.

This was followed up by PURPOSE 2, which expanded the geographical area significantly to more countries on more continents, and expanded the pool of individuals from beyond just young women to men—and to those of all ages. 5,000 participants took part.

The result was the same: 99.9% reduction in infection rates.

Both were considered phase 3 clinical trials, and were conducted in a randomized, double-blinded protocol, but were not tested against a placebo. Instead, the Lenacapavir injections were compared to the current standard of HIV prevention—a pill called Truvada or Descovy taken daily.

These both were also found to prevent HIV transmission by 99.9% during development, but must be taken every day to achieve this level of protection. As anyone who’s tried to stick to a once-a-day pill regime long-term will agree, it’s not an easy thing to maintain month after month.

By contrast, the twice-yearly injections are much easier to adhere to, and they also come with the added benefit of removing the social stigma of being seen taking a daily pill and therefore at risk of HIV transmission. This can be particularly alleviating in high-HIV-prevalent countries where male homosexuality is illegal, such as Uganda.

Indeed the superiority of a twice-yearly injection was so clear that both PURPOSE trials were halted early over ethical reasons. A 52-week follow-up screened for HIV developments.

Lenacapavir was named by Science Magazine as the Breakthrough of the Year in 2024, and was approved by the FDA for use in humans under the brand name Yeztugo.

It works to break down the HIVs capsid shell by binding to an “highly conserved” protein on the exterior. That means that no matter how many times or into what form the virus mutates, the exterior shell protein remains—presenting the perfect target for the drug.

In layman’s terms, the drug then works through the protein to disrupt the capsid shell, which the virus ‘takes down’ and ‘builds up’ several times during its lifecycle with perfect geometric precision. The disruption prevents the virus from completing its life cycle.

Initial R&D, regulation compliance, and proof of efficacy and safety requirements mean that producing Lenacapavir has cost its developer, Gilead Sciences, an undisclosed total cost that would be reasonable to estimate at well over a billion dollars based on normal pharma development costs.Gilead has nevertheless committed to providing the drug at cost in certain low-income regions and has licensed generic manufacturers to produce it for approximately $40 per year in 120 low and middle-income countries starting in 2027 Staggering Results Show HIV-Transmission Reduced 100% with Twice-Yearly Lenacapavir Injection

Read More........→July 17, 2026

Study Finds Many Older Adults Will Improve Over Time–Depending on Their Mindset

Getty Images for Unsplash +

A new study by scientists at Yale University suggests that older individuals can and do ‘improve,’ in all the senses of that word, over time.

Analyzing the results of a large study of older Americans that ran for a decade, a key data point was that the individual’s mindset toward aging plays a major part in their success.

If they believed aging was a process of decline, they declined. If they believed aging was a process of refinement, they improved.

Lead author Dr. Becca R. Levy, PhD, a professor of social and behavioral sciences at the Yale School of Public Health (YSPH) found that nearly half of adults aged 65 and older showed measurable improvement in cognitive function, physical function, or both, over time.

The improvements were not limited to a small group of exceptional individuals and, notably, were linked to a powerful but often overlooked factor: how people think about aging itself.

“Many people equate aging with an inevitable and continuous loss of physical and cognitive abilities,” said Dr. Levy, an international expert on psychosocial determinants of aging health. “What we found is that improvement in later life is not rare, it’s common, and it should be included in our understanding of the aging process.”

The findings are published in the journal Geriatrics.

For the study, the researchers followed more than 11,000 participants in the Health and Retirement Study, a federally supported longitudinal survey of older Americans. The research team tracked changes in cognition using a global performance assessment, and physical function using walking speed—often described by geriatricians as a “vital sign” because of its strong links to disability, hospitalization, and mortality.

Over a follow-up period of up to 12 years, 45% of participants improved in at least one of the two domains, according to the study. About 32% improved cognitively, 28% improved physically, and many experienced gains that exceeded thresholds considered clinically meaningful.

When participants whose cognitive scores remained stable over that period (rather than declining) were included, more than half defied the stereotype of inevitable deterioration in cognition.

“What’s striking is that these gains disappear when you only look at averages,” said Dr. Levy, author of the book 

“If you average everyone together, you see decline,” Dr. Levy continued. “But when you look at individual trajectories, you uncover a very different story. A meaningful percentage of the older participants that we studied got better.”

As for why, Levy and her co-authors hypothesized that an important factor could be participants had assimilated more positive or more negative views about aging by the start of the study. In support of this hypothesis, they found that those with more positive age beliefs were significantly more likely to show improvements in both cognition and walking speed, even after accounting for factors such as age, sex, education, chronic disease, depression, and length of follow-up.

The findings build on Dr. Levy’s stereotype embodiment theory, which posits that age stereotypes absorbed through a range of domains including social media and advertisements eventually become self-relevant and biologically consequential.

Credit: Getty Images for Unsplash+

Dr. Levy’s prior studies have found negative age beliefs predict poorer memory, slower walking speed, higher cardiovascular risk, and biomarkers associated with Alzheimer’s disease. The current study shows that those who have assimilated more positive age beliefs often show improvement, Dr. Levy said.

“Our findings suggest there is often a reserve capacity for improvement in later life,” she said. “And because age beliefs are modifiable, this opens the door to interventions at both the individual and societal level.”

The improvements were not limited to people who started out with impairments. Even among participants who had normal cognitive or physical function at baseline, a substantial proportion improved over time. That challenges the assumption that later-life gains reflect only people getting better after being sick or rebounding from earlier setbacks, the authors said.

The authors hope their findings will reverse the popular perception that continuous decline is inevitable and encourage policy makers to increase their support for preventive care, rehabilitation, and other health-promoting programs for older persons that draw on their potential resilience. https://www.goodnewsnetwork.org/new-study-finds-many-older-adults-can-and-do-improve-over-time-depending-on-their-mindset/

Read More........→June 25, 2026